https://myrtellegtx.com/ 2025-09-18T21:56:35+00:00 https://myrtellegtx.com/resources/ 2024-03-20T18:21:34+00:00 https://myrtellegtx.com/pelizaeus-merzbacher-disease/ 2024-01-24T16:42:16+00:00 https://myrtellegtx.com/multiple-system-atrophy/ 2024-01-24T16:40:08+00:00 https://myrtellegtx.com/h-abc/ 2024-01-24T16:41:39+00:00 https://myrtellegtx.com/dfnb-8/ 2023-12-07T18:22:41+00:00 https://myrtellegtx.com/canavan-treatment/ 2024-01-29T16:02:32+00:00 https://myrtellegtx.com/privacy-policy/ 2023-09-14T03:18:22+00:00 https://myrtellegtx.com/inquire/ 2023-09-25T18:50:06+00:00 https://myrtellegtx.com/canavan-disease/ 2024-11-21T17:25:03+00:00 https://myrtellegtx.com/clinical-trials/ 2024-01-24T18:06:41+00:00 https://myrtellegtx.com/news/ 2023-09-14T03:13:42+00:00 https://myrtellegtx.com/team/ 2025-09-22T17:29:01+00:00 https://myrtellegtx.com/technology/ 2024-02-05T15:54:37+00:00 https://myrtellegtx.com/pipeline/ 2024-01-24T16:39:03+00:00 https://myrtellegtx.com/about/ 2024-02-05T15:51:48+00:00 https://myrtellegtx.com/the-rare-disease-conversation-is-getting-louder-heres-where-myrtelle-stands/ 2026-03-25T13:29:33+00:00 https://myrtellegtx.com/rare-disease-day-lighting-the-path-for-the-canavan-community/ 2026-03-05T15:34:40+00:00 https://myrtellegtx.com/resource/advancements-in-canavan-disease-treatment-and-research-2/ 2025-12-22T19:33:16+00:00 https://myrtellegtx.com/resource/advancements-in-canavan-disease-treatment-and-research/ 2025-12-22T19:25:04+00:00 https://myrtellegtx.com/myrtelle-announces-presentation-of-encouraging-interim-results-from-its-phase-1-2-gene-therapy-trial-for-canavan-disease-at-the-2025-cell-gene-meeting-on-the-mesa/ 2025-10-06T16:17:04+00:00 https://myrtellegtx.com/team_members/debaditya-bhattacharya/ 2025-09-22T17:28:20+00:00 https://myrtellegtx.com/myrtelle-announces-nature-medicine-publication-of-interim-results-from-its-phase-1-2-clinical-trial-of-investigational-gene-therapy-raav-olig001-aspa-for-canavan-disease/ 2025-09-22T17:34:01+00:00 https://myrtellegtx.com/resource/the-link-between-white-matter-and-leukodystrophies/ 2025-12-22T19:30:54+00:00 https://myrtellegtx.com/resource/leukodystrophies-and-the-brains-fragile-wiring-a-fight-for-function/ 2025-07-08T18:47:56+00:00 https://myrtellegtx.com/myrtelle-launches-commercial-stage-manufacturing-of-first-in-class-gene-therapy-for-canavan-disease/ 2025-07-08T11:44:36+00:00 https://myrtellegtx.com/resource/how-gene-therapy-is-revolutionizing-the-canavan-disease-treatment-market/ 2025-07-03T14:58:16+00:00 https://myrtellegtx.com/myrtelle-to-present-breakthrough-insights-at-asgct-2025-new-orleans/ 2025-05-12T17:07:57+00:00 https://myrtellegtx.com/resource/white-matter-disease-whats-the-role-of-dna/ 2025-07-03T14:55:08+00:00 https://myrtellegtx.com/resource/white-matter-disease-in-the-brain-understanding-the-breakdown-of-neural-pathways/ 2025-04-23T22:23:17+00:00 https://myrtellegtx.com/resource/what-is-leukodystrophy-dissecting-the-disorder/ 2025-04-21T16:26:31+00:00 https://myrtellegtx.com/resource/exploring-the-advances-in-canavan-disease-gene-therapy/ 2025-04-10T20:27:30+00:00 https://myrtellegtx.com/resource/canavan-disease-symptoms-spotting-the-hidden-progressions-and-next-steps/ 2025-03-25T15:24:32+00:00 https://myrtellegtx.com/resource/understanding-myelin-degeneration-and-white-matter-disease-repair/ 2025-03-13T15:10:41+00:00 https://myrtellegtx.com/resource/the-future-outlook-of-the-canavan-disease-treatment-market/ 2025-03-05T20:11:40+00:00 https://myrtellegtx.com/resource/advances-in-white-matter-disease-research-and-emerging-treatments/ 2025-02-13T17:59:26+00:00 https://myrtellegtx.com/resource/breaking-ground-study-highlights-the-efficacy-of-myrtelles-aav-olig001-gene-therapy/ 2025-01-22T22:20:07+00:00 https://myrtellegtx.com/resource/the-crucial-steps-to-take-when-your-child-has-canavan-disease-diagnosis/ 2025-01-22T22:22:52+00:00 https://myrtellegtx.com/team_members/jordana-holovach-2/ 2025-01-21T17:13:06+00:00 https://myrtellegtx.com/resource/understanding-white-matter-diseases-the-hidden-disorders-affecting-brain-health/ 2025-01-08T17:04:42+00:00 https://myrtellegtx.com/resource/understanding-canavan-disease-inheritance/ 2025-01-08T16:59:39+00:00 https://myrtellegtx.com/resource/how-oligodendrocyte-function-influences-white-matter-disease/ 2025-01-08T16:38:20+00:00 https://myrtellegtx.com/resource/recognizing-canavan-disease-in-infants-key-signs-and-steps-for-early-intervention/ 2025-01-08T17:07:21+00:00 https://myrtellegtx.com/resource/spotting-the-early-symptoms-of-canavan-disease/ 2025-01-08T17:08:27+00:00 https://myrtellegtx.com/team_members/alicia-fiscus/ 2024-11-06T14:46:20+00:00 https://myrtellegtx.com/team_members/michael-muhonen/ 2024-11-13T23:21:23+00:00 https://myrtellegtx.com/team_members/josh-merritt/ 2024-10-31T16:58:20+00:00 https://myrtellegtx.com/resource/white-matter-diseases-rare-but-crucial-conditions-that-demand-our-attention/ 2024-10-29T00:58:19+00:00 https://myrtellegtx.com/resource/what-are-oligodendrocytes-understanding-their-function-in-brain-protection/ 2024-10-17T17:00:59+00:00 https://myrtellegtx.com/myrtelle-announces-significant-reduction-in-n-acetylaspartate-naa-a-key-biomarker-in-patients-treated-in-its-phase-1-2-clinical-trial-of-the-investigational-gene-therapy-raav-olig001-aspa-for-cana/ 2024-10-01T14:45:44+00:00 https://myrtellegtx.com/resource/the-future-of-precision-medicine-advanced-gene-therapies-for-rare-neurological-disorders/ 2024-09-26T16:49:14+00:00 https://myrtellegtx.com/resource/understanding-myelin-degeneration-in-canavan-disease/ 2024-09-26T16:50:05+00:00 https://myrtellegtx.com/resource/the-role-of-dna-in-gene-therapy-and-genetics/ 2024-09-20T17:41:57+00:00 https://myrtellegtx.com/resource/unlocking-possibilities-myrtelles-precision-vector-targeting-technology/ 2024-08-27T17:44:22+00:00 https://myrtellegtx.com/resource/canavan-disease-awareness-the-impact-of-myrtelle-and-global-effort/ 2024-08-29T15:55:38+00:00 https://myrtellegtx.com/resource/canavan-disease-shedding-light-on-a-genetic-mystery/ 2024-07-08T19:53:53+00:00 https://myrtellegtx.com/resource/detecting-canavan-disease-key-indicators-to-recognize/ 2024-07-04T14:54:06+00:00 https://myrtellegtx.com/resource/how-technology-can-advance-gene-delivery-in-canavan-disease/ 2024-07-26T16:14:07+00:00 https://myrtellegtx.com/resource/canavan-disease-insights-gene-therapy-administration/ 2024-06-06T00:57:32+00:00 https://myrtellegtx.com/fda-selects-myrtelle-for-start-pilot-program/ 2024-10-01T14:11:57+00:00 https://myrtellegtx.com/now-available-myrtelle-asgct-symposium-presentation/ 2024-06-03T17:13:54+00:00 https://myrtellegtx.com/symposium-canavan-asgct-may-8/ 2024-05-06T17:22:28+00:00 https://myrtellegtx.com/team_members/adrian-stecyk/ 2024-05-01T17:27:15+00:00 https://myrtellegtx.com/resource/canavan-disease-symptoms-and-their-relation-to-age/ 2024-07-26T16:15:05+00:00 https://myrtellegtx.com/resource/phase-1-2-clinical-trial-paving-a-path-of-hope-for-canavan-disease/ 2024-07-26T16:16:13+00:00 https://myrtellegtx.com/resource/canavan-disease-what-causes-this-rare-condition/ 2024-04-10T20:08:31+00:00 https://myrtellegtx.com/resource/canavan-disease-understanding-its-origins/ 2024-04-10T20:05:54+00:00 https://myrtellegtx.com/resource/unlocking-miracles-new-gene-therapy-research-offers-optimism-for-patients/ 2024-04-10T14:26:37+00:00 https://myrtellegtx.com/myrtelles-raav-olig001-aspa-gene-therapy-candidate-for-canavan-disease-receives-regenerative-medicine-advanced-therapy-rmat-designation-from-the-u-s-food-and-drug-administration/ 2024-05-05T22:42:46+00:00 https://myrtellegtx.com/resource/the-new-understanding-of-the-impact-of-oligodendrocytes-in-brain-function-and-their-role-in-brain-disorders/ 2024-04-10T13:32:46+00:00 https://myrtellegtx.com/inheritance-patterns-of-canavan-disease-navigating-options-when-only-one-mutation-is-identified/ 2024-05-05T22:10:31+00:00 https://myrtellegtx.com/exciting-update-explore-myrtelles-insightful-slide-presentation-on-gene-therapy-for-canavan-disease-preliminary-one-year-results-from-meeting-on-the-mesa/ 2023-12-07T21:07:53+00:00 https://myrtellegtx.com/myrtelle-announces-presentation-at-the-5th-annual-gene-therapy-for-neurological-disorders-summit-optimizing-gene-therapies-targeting-the-cns-to-deliver-safe-efficacious-treatment-options-for-neurol/ 2023-12-07T20:55:38+00:00 https://myrtellegtx.com/myrtelle-announces-presentation-of-positive-12-month-post-treatment-data-in-its-first-in-human-clinical-study-of-raav-olig001-aspa-gene-therapy-at-the-2023-cell-gene-meeting-on-the-mesa-held-by/ 2023-12-07T17:22:49+00:00 https://myrtellegtx.com/myrtelle-announces-presentation-at-hydrocephalus-association-rudi-schulte-research-workshop-on-developing-non-invasive-hydrocephalus-therapies-molecular-and-cellular-targets/ 2023-12-07T17:23:18+00:00 https://myrtellegtx.com/team_members/cassandra-santiago/ 2023-09-27T15:02:45+00:00 https://myrtellegtx.com/team_members/thomas-madore/ 2025-03-11T14:32:44+00:00 https://myrtellegtx.com/team_members/richard-layer/ 2025-03-03T15:47:38+00:00 https://myrtellegtx.com/team_members/jordana-holovach/ 2024-11-17T21:29:03+00:00 https://myrtellegtx.com/team_members/olga-flamini/ 2024-11-19T15:56:01+00:00 https://myrtellegtx.com/asgct-2023/ 2023-12-07T17:24:14+00:00 https://myrtellegtx.com/dr-janson-asgct2023/ 2023-12-07T17:26:28+00:00 https://myrtellegtx.com/myrtelle-to-present-positive-6-month-post-treatment-data-in-its-first-in-human-clinical-study-of-raav-olig001-aspa-gene-therapy-in-canavan-disease-at-the-national-tay-sachs-and-allied-diseases-annual/ 2024-02-26T20:44:25+00:00 https://myrtellegtx.com/myrtelle-announces-presentation-of-positive-6-month-post-treatment-data-in-its-first-in-human-clinical-study-of-raav-olig001-aspa-gene-therapy-in-canavan-disease-at-the-american-society-of-gene-and-ce/ 2024-02-26T20:47:00+00:00 https://myrtellegtx.com/myrtelle-to-host-symposium-at-asgct/ 2024-02-26T20:46:03+00:00 https://myrtellegtx.com/myrtelles-raav-olig001-aspa-gene-therapy-candidate-for-canavan-disease-receives-innovative-licensing-and-access-pathway-designation-from-the-uk-medicines-and-healthcare-products-regulatory-ag/ 2024-02-26T20:48:23+00:00 https://myrtellegtx.com/myrtelle-announces-positive-6-month-post-treatment-data-in-patients-in-its-first-in-human-clinical-study-of-raav-olig001-aspa-gene-therapy-in-canavan-disease/ 2024-02-26T20:49:03+00:00 https://myrtellegtx.com/myrtelle-and-raaven-therapeutics-to-develop-novel-gene-therapy-vectors/ 2023-12-07T17:30:52+00:00 https://myrtellegtx.com/myrtelle-announces-positive-interim-data-in-phase-1-2-clinical-trial-of-its-proprietary-investigational-gene-therapy-raav-olig001-aspa-in-canavan-disease/ 2023-12-07T17:31:34+00:00 https://myrtellegtx.com/myrtelles-raav-olig001-aspa-gene-therapy-candidate-for-canavan-disease-receives-orphan-drug-designation-from-the-european-medicines-agency/ 2023-12-07T17:32:04+00:00 https://myrtellegtx.com/naa-q-a-with-dr-janson/ 2023-12-07T17:38:42+00:00 https://myrtellegtx.com/resource/q-a-the-power-of-the-patient-in-a-clinical-trial/ 2024-03-25T18:24:03+00:00 https://myrtellegtx.com/myrtelle-completes-dosing-of-8-patients-with-canavan-disease-in-its-phase-1-2-clinical-trial-of-the-investigational-gene-therapy-raav-olig001-aspa/ 2023-12-07T17:39:55+00:00 https://myrtellegtx.com/myrtelle-and-forge-biologics-announce-viral-vector-and-plasmid-dna-cgmp-manufacturing-partnership/ 2023-12-07T17:44:38+00:00 https://myrtellegtx.com/myrtelles-raav-olig001-aspa-gene-therapy-candidate-for-canavan-disease-receives-advanced-therapy-medicinal-product-classification-from-the-european-medicines-agency/ 2023-12-07T17:45:12+00:00 https://myrtellegtx.com/resource/qa-with-christopher-j-morrison-senior-vice-president-of-technical-operations/ 2024-03-25T18:23:29+00:00 https://myrtellegtx.com/oligodendrocytes-video/ 2023-12-07T17:46:02+00:00 https://myrtellegtx.com/myrtelle-announces-positive-data-for-its-investigational-proprietary-raav-olig001-aspa-gene-therapy-in-canavan-disease-at-the-national-tay-sachs-allied-diseases-association-conference/ 2023-12-07T17:46:23+00:00 https://myrtellegtx.com/resource/qa-with-richard-layer-vice-president-head-of-pharmacology/ 2024-03-25T18:22:42+00:00 https://myrtellegtx.com/myrtelle-enters-into-a-worldwide-exclusive-license-agreement-with-rescue-hearing-to-develop-and-commercialize-gene-therapy-for-the-treatment-of-hearing-loss/ 2023-12-07T17:50:38+00:00 https://myrtellegtx.com/myrtelle-inc-announces-expansion-of-its-pipeline-with-a-novel-gene-therapy-program-for-pelizaeus-merzbacher-disease-pmd/ 2023-10-06T20:12:07+00:00 https://myrtellegtx.com/resource/qa-with-nancy-barone-kribbs-senior-vice-president-global-regulatory-affairs/ 2024-03-25T18:22:11+00:00 https://myrtellegtx.com/myrtelle-receives-fda-fast-track-rare-pediatric-disease-and-orphan-drug-designations-for-its-proprietary-gene-therapy-for-the-treatment-of-canavan-disease/ 2023-12-07T18:50:41+00:00 https://myrtellegtx.com/resource/q-a-with-armen-asatryan-md-mph-chief-medical-officer/ 2024-03-25T18:21:40+00:00 https://myrtellegtx.com/myrtelle-announces-positive-preliminary-clinical-data-for-its-proprietary-gene-therapy-in-canavan-disease/ 2023-12-07T18:51:36+00:00 https://myrtellegtx.com/myrtelle-announces-successful-completion-of-initial-stage-of-phase-1-2-clinical-trial-of-proprietary-gene-therapy-for-canavan-disease-and-expands-treatment-to-younger-patients/ 2023-12-07T18:52:01+00:00 https://myrtellegtx.com/myrtelle-announces-exclusive-worldwide-gene-therapy-licensing-agreement-for-canavan-disease/ 2023-12-07T18:52:28+00:00 https://myrtellegtx.com/health-care-hero-dayton-childrens-doctor-offers-hope-groundbreaking-clinical-trials-for-patients/ 2023-12-07T18:52:57+00:00